Invivyd, Inc. Q2 FY2024 earnings call

• Leadership transition at Invivyd aimed to expand corporate ambition and improve delivery of medical value for vulnerable populations, with immediate initiatives to enhance operational posture and efficiency. • Rapidly expanding commercial footprint and pipeline advancement were noted, though early net revenue results were not satisfactory but showed consistent growth in Q2 with acceleration in early 3Q. • Tim Lee joined as Chief Commercial Officer, onboarded experienced team, worked on commercialization of PEMGARDA, including refining commercial launch metrics, preparing an activation campaign, and engaging with healthcare providers. • VYD2311 pipeline advancement with Australian ethics approval for first-in-human study, planning to interrogate multiple routes of administration. • Discussion on virology, surrogate markers for COVID-19 antibodies, and evolving approach to address virus evolution, leveraging structural biology and discovery platform. • Streamlining operations and burn rate related to production of VYD2311, with plans to transition to it after exhausting PEMGARDA supply.

No specific financial performance details for product segments in absolute terms and revenue contribution percentages were provided in the transcript.

• Reaffirmed revenue and cash guidance provided previously, with plans to refine guidance in the fall. • Focus on the upcoming commercial push in the fall/winter respiratory virus season, anticipating significant activity as the season approaches.

• Virus evolution can quickly obsoleter single SVNA titer point estimates and affect antibody potency. • Variability in assay systems limits the accuracy of analyses related to antibody potency and regulatory actions. • Challenges in maintaining consistent efficacy across different virus variants, though Invivyd aims to leverage conserved epitopes to mitigate this.

Q: Tim, perspective on optimizing success, summer wave, and fall immunization season A: Tim Lee discussed bringing on a seasoned team, starting digital work, increasing corporate campaign work, updating PEMGARDA infusion locator, noting over 200 sites, engaging with the patient community, and focusing on the immunocompromised population's needs Q: EUA status, magnitude of opportunity, availability of infusion sites A: Marc Elia stated EUA submission is done and in discussion with FDA, magnitude of treatment opportunity not quantifiable yet; Tim Lee mentioned infusion locator is being updated in real time, with efforts to reach major academic medical centers and private infusion sites Q: OUS status, visibility on ordering A: Marc Elia talked about OUS exploration under constant discussion, with focus on VYD2311 due to PEMGARDA supply constraints; visibility on ordering noted an acceleration in Q3 with major activity expected in fall/winter respiratory virus season